ACNU-cisplatin Continuous Infusion Chemotherapy As Salvage Therapy for Recurrent Glioblastomas: Phase II Study

Overview

Journal J Neurooncol

Publisher Springer

Date 2005 Sep 1

PMID 16132508

Citations 9

Authors

Ho-Shin Gwak

Sang-Min Youn

Austin-Hyuk Kwon

Seung Hoon Lee

Jong Hyun Kim

Chang Hun Rhee

Affiliations

Soon will be listed here.

Abstract

Purpose: To evaluate the activity and the toxicity of ACNU (1-(4-amino-2-methyl-5-pyrimidinyl)-methyl-3-(2-cholroethyl)-3-nitrosourea hydrochloride) administered with cisplatin by intravenous infusion for 72 h in select patients with recurrent glioblastoma.

Patients And Methods: From April 1996 to 2002, 37 patients with histologically proven glioblastoma, who showed recurrence on image study after operation and radiation, met the eligibility criteria of our cohort. The mean time to recurrence was 9.7+/-7.0 (1-26 months). Treatment response was evaluated every 6 weeks using magnetic resonance imaging (MRI). Complete blood counts were collected every week to monitor and treat possible bone marrow suppression from the treatment. Survival rates were analyzed using the Kaplan-Meier and log rank test.

Results: Post-chemotherapy MRI was available in 36 of 37 patients. Response to treatment was observed in 19 patients (53%) including two cases of complete remission. Six patients (17%) showed progression (PD) and 11 patients (31%) had stable disease (SD). Two or more cycles of chemotherapy was the only factor that predicted response to treatment. The overall median survival for all patients was 17.0+/-5.5 months. Age (< 40 years) and time to recurrence (>or=1 year) were the clinical factors that predicted improved overall survival. Survival gain after chemotherapy was 9 months. Patients who responded and those with SD after treatment (11 months) had a longer median survival compared to PD (5 months) (P=0.01). Myelosuppression was severe (grade III/IV leukopenia in 15 patients (40%) and grade III/IV thrombocytopenia in 19 patients (52%)) but most recovered more than WHO grade II at the end of the chemotherapy cycles. There was only one fatality due to sepsis from pneumonia during the initial leukopenic state.

Conclusion: ACNU and cisplatin chemotherapy can be an effective salvage therapy for recurrent glioblastoma patients. Myelosuppression from the chemotherapy regimen was the greatest side-effect but was manageable.

Citing Articles

Advances in research on the carcinogenic mechanisms and therapeutic potential of YAP1 in bladder cancer (Review).

Huang T, Fan L, Tang J, Chen S, Du G, Zhang N Oncol Rep. 2024; 53(1).

PMID: 39540392 PMC: 11599795. DOI: 10.3892/or.2024.8843.

Procarbazine and CCNU Chemotherapy for Recurrent Glioblastoma with MGMT Promoter Methylation.

Kim S, Yoo H, Chang J, Kim C, Chung D, Kim S J Korean Med Sci. 2018; 33(24):e167.

PMID: 29892208 PMC: 5990446. DOI: 10.3346/jkms.2018.33.e167.

The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.

Olson J, Nayak L, Ormond D, Wen P, Kalkanis S J Neurooncol. 2014; 118(3):501-55.

PMID: 24740194 DOI: 10.1007/s11060-013-1338-5.

Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated patients with recurrent glioblastoma: a single-institution analysis.

Kuhnhenn J, Kowalski T, Steenken S, Ostermann K, Schlegel U J Neurooncol. 2012; 109(2):433-8.

PMID: 22744756 DOI: 10.1007/s11060-012-0913-5.

Chemotherapy for malignant gliomas based on histoculture drug response assay : a pilot study.

Gwak H, Park H, Yoo H, Youn S, Rhee C, Lee S J Korean Neurosurg Soc. 2012; 50(5):426-33.

PMID: 22259689 PMC: 3259462. DOI: 10.3340/jkns.2011.50.5.426.

References

Barker 2nd F, Chang S, Gutin P, Malec M, McDermott M, PRADOS M . Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery. 1998; 42(4):709-20; discussion 720-3. DOI: 10.1097/00006123-199804000-00013. View

van den Bent M, Grisold W, Frappaz D, Stupp R, Desir J, Lesimple T . European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme. Ann Oncol. 2003; 14(12):1732-4. DOI: 10.1093/annonc/mdg491. View

Walker M, Green S, Byar D, ALEXANDER Jr E, Batzdorf U, Brooks W . Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980; 303(23):1323-9. DOI: 10.1056/NEJM198012043032303. View

WAKUI A . [Cancer chemotherapy with special reference to pharmacokinetics of nitrosoureas]. Gan To Kagaku Ryoho. 1982; 9(8):1327-38. View

Prados M, Rodriguez L, Chamberlain M, Silver P, Levin V . Treatment of recurrent gliomas with 1,3-bis(2-chloroethyl)-1-nitrosourea and alpha-difluoromethylornithine. Neurosurgery. 1989; 24(6):806-9. DOI: 10.1227/00006123-198906000-00003. View

Iwadate Y, Namba H, Sueyoshi K . Intra-arterial ACNU and cisplatin chemotherapy for the treatment of glioblastoma multiforme. Neurol Med Chir (Tokyo). 1995; 35(8):598-603. DOI: 10.2176/nmc.35.598. View

Choi I, Lee S, Kim T, Bang J, Paek S, Kim S . Phase II study of chemotherapy with ACNU plus cisplatin followed by cranial irradiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol. 2003; 60(2):171-6. DOI: 10.1023/a:1020605617452. View

Hochberg F, Parker L, Takvorian T, Canellos G, Zervas N . High-dose BCNU with autologous bone marrow rescue for recurrent glioblastoma multiforme. J Neurosurg. 1981; 54(4):455-60. DOI: 10.3171/jns.1981.54.4.0455. View

Gerosa M, Rosenblum M, Stevanoni G, Licata C, Della Corte V, Marcon C . In vitro analysis of BCNU-sensitivity in human malignant gliomas. II. Cross-resistance studies with cisplatinum and nitrosoureas. Acta Neurol Scand. 1986; 73(1):66-70. DOI: 10.1111/j.1600-0404.1986.tb03242.x. View

10.

Stewart D, OBRYAN R, Al-Sarraf M, COSTANZI J, Oishi N . Phase II study of cisplatin in recurrent astrocytomas in adults: a Southwest Oncology Group Study. J Neurooncol. 1983; 1(2):145-7. DOI: 10.1007/BF00182960. View

11.

Qin D, Zheng R, Tang J, Li J, Hu Y . Influence of radiation on the blood-brain barrier and optimum time of chemotherapy. Int J Radiat Oncol Biol Phys. 1990; 19(6):1507-10. DOI: 10.1016/0360-3016(90)90364-p. View

12.

Hau P, Baumgart U, Pfeifer K, Bock A, Jauch T, Dietrich J . Salvage therapy in patients with glioblastoma: is there any benefit?. Cancer. 2003; 98(12):2678-86. DOI: 10.1002/cncr.11845. View

13.

Kondziolka D, Flickinger J, Bissonette D, Bozik M, Lunsford L . Survival benefit of stereotactic radiosurgery for patients with malignant glial neoplasms. Neurosurgery. 1997; 41(4):776-83; discussion 783-5. DOI: 10.1097/00006123-199710000-00004. View

14.

Tsuboi K, Yoshii Y, Hyodo A, Takada K, Nose T . Leukoencephalopathy associated with intra-arterial ACNU in patients with gliomas. J Neurooncol. 1995; 23(3):223-31. DOI: 10.1007/BF01059953. View

15.

Kleinberg L, Grossman S, Piantadosi S, Zeltzman M, Wharam M . The effects of sequential versus concurrent chemotherapy and radiotherapy on survival and toxicity in patients with newly diagnosed high-grade astrocytoma. Int J Radiat Oncol Biol Phys. 1999; 44(3):535-43. DOI: 10.1016/s0360-3016(99)00060-7. View

16.

Dirks P, Bernstein M, Muller P, TUCKER W . The value of reoperation for recurrent glioblastoma. Can J Surg. 1993; 36(3):271-5. View

17.

Paoletti P, Butti G, Knerich R, Gaetani P, Assietti R . Chemotherapy for malignant gliomas of the brain: a review of ten-years experience. Acta Neurochir (Wien). 1990; 103(1-2):35-46. DOI: 10.1007/BF01420190. View

18.

Stewart D, Leavens M, Maor M, Feun L, Luna M, Bonura J . Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res. 1982; 42(6):2474-9. View

19.

Yung W, Janus T, Maor M, Feun L . Adjuvant chemotherapy with carmustine and cisplatin for patients with malignant gliomas. J Neurooncol. 1992; 12(2):131-5. DOI: 10.1007/BF00172662. View

20.

Qin D, Ou G, Mo H, Song Y, Kang G, Hu Y . Improved efficacy of chemotherapy for glioblastoma by radiation-induced opening of blood-brain barrier: clinical results. Int J Radiat Oncol Biol Phys. 2001; 51(4):959-62. DOI: 10.1016/s0360-3016(01)01735-7. View